Stockreport

Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF –Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA––Changes in visual function, ocular structure and quality of li [Read more]